The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review
暂无分享,去创建一个
V. Tombolini | F. Torcia | V. De Sanctis | A. Vavassori | A. Colombo | M. Osti | M. Mangoni | D. Musio | F. Bellati | L. Tagliaferri | V. Lancellotta | L. Vicenzi | A. Cerrotta | F. De Felice | F. Marampon | S. Gribaudo | S. Costantini | D. di Cristino | A. Antonacci | V. Cerboneschi | Francesco Lucà | R. Barbara
[1] Jae-Weon Kim,et al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Giovagnoni,et al. Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey , 2019, Journal of contemporary brachytherapy.
[3] A. Barcellini,et al. Vaginal toxicity after high-dose-rate endovaginal brachytherapy: 20 years of results , 2018, Journal of contemporary brachytherapy.
[4] G. Pond,et al. Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer , 2018, Cureus.
[5] V. Valentini,et al. EROS study: evaluation between high-dose-rate and low-dose-rate vaginal interventional radiotherapy (brachytherapy) in terms of overall survival and rate of stenosis , 2018, Journal of contemporary brachytherapy.
[6] F. Vianello,et al. A new standardized data collection system for interdisciplinary thyroid cancer management: Thyroid COBRA. , 2018, European journal of internal medicine.
[7] R. Autorino,et al. A national survey of AIRO (Italian Association of Radiation Oncology) brachytherapy (Interventional Radiotherapy) study group , 2018, Journal of contemporary brachytherapy.
[8] V. Valentini,et al. ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy) , 2018, Journal of contemporary brachytherapy.
[9] J. Kwon,et al. The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis. , 2018, Gynecologic oncology.
[10] M. Shruthi,et al. Combined external beam radiotherapy and vaginal brachytherapy versus vaginal brachytherapy in stage I, intermediate- and high-risk cases of endometrium carcinoma , 2018, Journal of contemporary brachytherapy.
[11] V. Valentini,et al. Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience , 2017, Journal of contemporary brachytherapy.
[12] L. Azario,et al. Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma , 2017, Journal of contemporary brachytherapy.
[13] M. Elshaikh,et al. External pelvic and vaginal irradiation vs. vaginal irradiation alone as postoperative therapy in women with early stage uterine serous carcinoma: Results of a National Cancer Database analysis. , 2017, Brachytherapy.
[14] Vincenzo Valentini,et al. ENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy) , 2016, Journal of contemporary brachytherapy.
[15] M. Köbel,et al. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. , 2015, Gynecologic oncology.
[16] J. Carrier,et al. Adjuvant Chemotherapy and Vaginal Vault Brachytherapy With or Without Pelvic Radiotherapy for Stage 1 Papillary Serous or Clear Cell Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.
[17] S. Waggoner,et al. Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma , 2015 .
[18] S. Waggoner,et al. Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study. , 2015, Gynecologic oncology.
[19] R. Den,et al. Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer , 2014, Journal of contemporary brachytherapy.
[20] J. Debus,et al. Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy , 2014, Radiation oncology.
[21] V. Strnad,et al. Intraluminal brachytherapy in oesophageal cancer: defining its role and introducing the technique , 2014, Journal of contemporary brachytherapy.
[22] R. Barakat,et al. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy. , 2013, Gynecologic oncology.
[23] M. Birrer,et al. Uterine papillary serous cancer: a review of the literature. , 2012, Gynecologic oncology.
[24] R. Barakat,et al. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. , 2012, Gynecologic oncology.
[25] A. Secord,et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). , 2009, Gynecologic oncology.
[26] P. Gehrig,et al. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.
[27] L. Havrilesky,et al. Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma , 2009, Cancer.
[28] D. Cella,et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. , 2009, Gynecologic oncology.
[29] R. Naumann. Uterine papillary serous carcinoma: State of the state , 2008, Current oncology reports.
[30] V. Valentini,et al. Videoconferencing to enhance the integration between clinical medicine and teaching: a feasibility study. , 2008, Tumori.
[31] D. Mutch,et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. , 2008, Gynecologic oncology.
[32] M. Carey,et al. Is adjuvant therapy necessary for Stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? , 2007, International Journal of Gynecologic Cancer.
[33] M. Hendrickson,et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.
[34] T. Roy,et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. , 2006, Gynecologic oncology.
[35] P. Boyle,et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. , 2004, Gynecologic oncology.
[36] R. Burger,et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] S. McDonald,et al. High-dose rate brachytherapy for Stage I/II papillary serous or clear cell endometrial cancer. , 2004, Gynecologic oncology.
[38] R. Bentley,et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] R. Burger,et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] R. Broaddus,et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. , 2003, Gynecologic oncology.
[41] R. Burger,et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] A. Mundt,et al. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. , 2003, International journal of radiation oncology, biology, physics.
[43] V. Abeler,et al. Clear-cell and papillary serous cancer: treatment options. , 2001, Best practice & research. Clinical obstetrics & gynaecology.
[44] E. Trimble,et al. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. , 2001, Gynecologic oncology.
[45] M. Maiman,et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. , 1997, Gynecologic oncology.
[46] J. Nicklin,et al. Endometrial papillary serous carcinoma: patterns of spread and treatment. , 1996, Clinical obstetrics and gynecology.
[47] M. R. Smith,et al. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. , 1994, American journal of obstetrics and gynecology.
[48] R. Lotocki,et al. Papillary serous adenocarcinoma of the endometrium. , 1986, Obstetrics and gynecology.
[49] R. Kempson,et al. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma , 1982, The American journal of surgical pathology.
[50] R. Iezzi,et al. Interventional Oncology: Should Interventional Radiotherapy (Brachytherapy) be Integrated into Modern Treatment Procedures? , 2019, Turkish Journal of Oncology.
[51] D. Gaffney,et al. American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. , 2017, Brachytherapy.
[52] A. Tinker,et al. Population-based treatment and outcomes of Stage I uterine serous carcinoma. , 2014, Gynecologic oncology.
[53] A. Mariani,et al. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. , 2013, International journal of radiation oncology, biology, physics.
[54] M. Siddiqui,et al. Clinical outcomes of adjuvant chemotherapy and vaginal brachytherapy with or without pelvic radiation for surgical stage I-II uterine serous carcinoma. , 2012, European journal of gynaecological oncology.
[55] L. Wilson,et al. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. , 1998, International journal of radiation oncology, biology, physics.
[56] S. Lauchlan. Tubal (serous) carcinoma of the endometrium. , 1981, Archives of pathology & laboratory medicine.